文献リスト

1) Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006; 119: 912-9

2) Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK 1/2 in rat renal fibroblasts. Hypertension. 2005; 46: 1039-45

3) Miyata K. Rahman M, Shokoji T, et al. Aldosterone stimulated reactove oxygen species production through activation of NADPH oxydase in the rat mesangial cells. J Am Soc Nephrol. 2005; 16: 2906-12

4) Greece EL, Kren S, Hostetter TH. Roles of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996; 98: 1063-8

5) Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004; 93: 990-6

6) Fiebeler A, Nussberger J, Shagdarsuren E, et al. Aldosterone synthetase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005; 111: 3087-94

7) Funder JW. Aldosterone and mineralocorticoid receptors: orphan questions. Kidney Int. 2000; 57: 1358-63

8) Carvajal CA, Gonzalez AA, Romero DG, et al. Tow homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endcrinol Metab. 2003; 88: 2501-7

9) Frev FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens. 2004; 13: 451-8

10) Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens. 2000; 18: 241-8

11) Isomura Y, Mune T, Morita H, et al. Physiologic roles of 11beta-hydroxysteroid dehydrogenase type 2 in kidney. Metab Clin Exp. 2006; 55: 1352-7

12) Christ M, Sippel K, Eisen C, et al. Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol. 1994; 99: R31-4

13) Good DW. Nongenomic actions of aldosterone on the renal tubule. Hypertension. 2007; 49: 728-39

14) Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 2003; 83: 965-1016

15) Whiting KP, Restall CJ, Brian PF. Steroid hormone-indued effects on membrane fluidity and their potential roles in nongenomic mechanisms. Life Sci. 2000; 67: 743-57

16) Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension. 2005; 46: 584-90

17) Nishikawa T, Suematsu S, Saito J, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005; 96: 309-16

18) Kobayashi N, Hara K, Tojo A, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKC epsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005; 45: 538-44

19) Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for non-proteolytic activation of prorenin. J Clin Invest. 2004; 114: 1128-35

20) Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005; 45: 710-6

21) Yuan J, Jia R, Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol. 2007; 40: 180-8

22) Lai L, Chen J, Hao CM, et al. Aldosterone promotes fibronectin production through Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Comm. 2006; 348: 70-5

23) Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: roles of oxydative stress and Sgk1. Hypertension. 2007; 49: 355-64

24) Sun GP, Kohno, Guo P, et al. Involvements of Rho-kinase and TGF-beta pathways in aldo-sterone-induced renal injury. J Am Soc Nephrol. 2006; 17: 2193-201

25) Han KH, Kang YS, Han S-Y, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 2006; 70: 111-20

26) de las Haras N, Ruiz-Ortega M, Miana M, et al. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens. 2007; 25: 629-38

27) Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003; 14: 2255-63

28) Schmidt BM, Sammer U, Fleischman I, et al. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension. 2006; 47: 636-7

29) Mulatero P, Dluhy RG, Giacchetti G, et al. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrin Metabol. 2005; 16: 114-9

30) Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42: 161-5

31) Nishimura M, Uzu T, Kuroda S, et al. Cardio-vascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999; 33: 261-6

32) Ribstein J, Du Cailar G, Mimran A. Relative glomerular hyperfiltration in primary aldosteron-ism. J Am Soc Nephrol. 2005; 16: 1320-5

33) Rossi GP, Bernini G, Desideri G, et al. Renal damage in primart aldosteronism: results of the PAPY study. Hypertension. 2006; 48: 232-8

34) Sechi LA, Novello M, Lapenna R, et al. Long-term outcomes in patients with primary aldoste-ronism. JAMA. 2006; 14: 2638-45

35) Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41: 64-8

36) Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-23

37) Yamamuro, M, Yoshimura M, Nakayama M, et al. Direct effects of aldosterone on cardio-myocytes in the presence of normal and elevated extracellular sodium. Endocrinol. 2006; 147: 1314-21

38) Gu JW, Anand V, Shek EW, et al. Sodium induces hypertrophy of cultured myocardial blasts and vascular smooth muscle cells. Hypertension. 1998; 31: 1083-7

39) Kitiyara C, Chabrashvilli T, Chen Y, et al. Salt intake, oxidative stress and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003; 14: 2775-82

40) Gu JW, Tian N, Shparago M, et al. Renal NF-kappa B activation and TNF-alfa up-regulation corrlate with salt-sensitive hypertension in Dahl salt sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R1817-24

41) Franco M, Martinez F, Rodriguez-Iturbe B, et al. Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitve hypertension. Am J Physiol Renal. 2006; 291: F1281-7

42) Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in strok-prone spontaneously hypertensive rats. Hypertension. 2002; 40: 28-33

43) Fan YY, Baba R, Nagi Y, et al. Augumentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res. 2006; 29: 169-78

44) Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone es-cape phenomena in renin-angiotensin-aldoste-rone system blockade: is oral renin inhibition the solution？ Expert Opin Pharmacother. 2007; 8: 529-35

45) Wong S, Brennan FE, Young MJ, et al. A direct effecct of aldosterone on endothelin-1 gene expression in vivo. Endocrinol. 2007; 148: 1511-7

46) Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelin and their antagonists？ Curr Hypertens Rep. 2006; 8: 262- 8

47) Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropath of rats with metabolic syndrome: possible contri-bution of fat-derived factors. J Am Soc Nephrol. 2006; 17: 3438-46

48) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003; 100: 14211-6

49) Goodfriend TL, Ball DL, Egan BM, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004; 43: 358-63

50) 市原淳弘. 組織レニン・アンギオテンシン系調節機構. 腎と透析. 2006; 60: 319-22

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp